11th Annual Pharma Anti-Counterfeiting & Serialisation 2023
Share
Now
WHY SHOULD YOU ATTEND?
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
Event Speakers
LUIS PEREZ
FDA
LUIS PEREZ
FDA
LUIS PEREZ, Country Attache for UK, FDA Office of Criminal Investigations
Luis Perez was born in Ponce, Puerto Rico and was raised in Jacksonville, FL. He graduated from Florida State University in Tallahassee, FL in 1991 with a B.A. in International Affairs. In 1999, Luis obtained the certification of Certified Fraud Examiner (CFE) and has been a contributing member since that time.
He began his professional career in 1996 as a Special Agent in the U.S. Army Criminal Investigation Command (CID)with an assignment in Panama where he conducted numerous felony criminal investigations for the US Army in Central and South America involving violent, white collar and drug crimes ending his tenure there as the Group Supervisor for the Drug Suppression Team.Before that Luis was a Military Police Officer/Military Police Investigator in the U.S. Army from 1992 until his promotion to Special Agent in 1996.
Luis began with FDA OCI in October 2000 at the Miami Field Office. Luis conducted counterfeit, adulterated, and misbranded drugs, devices, as well as food and drug tampering investigations throughout the United States, the Caribbean and Central America affecting US Public Health and US Pharmaceutical companies. Luis supervised and managed a Task Force of several undercover officers conducting traditional FDA investigations.
In 2007, Luis departed for a position with the Defense Criminal Investigative Service (DCIS) where he supervised and managed an undercover task force which conducted Counter Proliferation investigations. Luis served as the DCIS lead representative at the International Contract and Corruption Task Force Afghanistan, Bagram, Afghanistan, conducting fraud investigations in Afghanistan where the Department of Defense had an interest.
In 2012, Luis returned to OCI and was assigned to the Miami Field Office where he supervised and managed a Task Force of several undercover officers conducting Tobacco related investigations as well as traditional FDA investigations. In 2016, Luis was promoted to Assistant Special Agent in Charge and had several different roles supervising at HQS, Budget, Contracts, Asset Forfeiture,the Investigative Analysis Branch, Facilities, Property, the Undercover Programs, and others. In 2021, Luis was selected to be FDA/OCI’s representative at the US Mission in the United Kingdom and reported to the embassy in January 2022. He is due to transfer back to the U.S. in January 2025.
Luis likes to spend his time hiking, biking, and running with his wife. Luis has two children, a daughter who graduated and now works at Florida State University (Go Noles!) and a son who is in his second year at the University of Florida.
THOMAS WELCH
Dept of Homeland Security
THOMAS WELCH
Dept of Homeland Security
THOMAS WELCH, Deputy Attache, London Office, Department of Homeland Security
HEATHER H
Genentech (USA)
HEATHER H
Genentech (USA)
HEATHER HENSON, Senior Director, Investigations and Intelligence, Genentech (USA)
• Heather Henson started her career as an Agent with the Secret Service.
• She worked numerous protection details for Presidents and then focused her attention on counterfeiting of US Currency.
• Later, she joined the FBI's counterterrorism task force and spent many months at ground zero right after 9/11.
• She also spent 2 years at the Federal Emergency Management Agency where she coordinated an Investigative team that was responsible for responding to national presidentially declared disasters.
• Next, she became the Senior Briefer in the White House where she covered all Homeland operations and intelligence briefings daily.
• Following the White House, Heather graduated with her Executive diploma from the Harvard Kennedy School and she went to work for the US Court system helping to write plans for how to continue operations during disasters.
• These days, you can find Heather working for Genentech/Roche as the Sr. Director for Investigations and Intelligence. Among other tasks, she runs the anti-counterfeiting team, threat assessment team, and asset protection team.
JYRKI SYVAERI
Boehringer Ingelheim
JYRKI SYVAERI
Boehringer Ingelheim
JYRKI SYVAERI, Corporate Director Supply Chain Integrity, Boehringer Ingelheim
• Jyrki Syväri, Pharmacist and Chemist, made his PhD Theses in Pharmaceutical Chemistry and his Diploma in Chemistry in Analytical Chemistry.
• He joined Schering AG in Berlin and headed there a R&D Laboratory for the development of parenteral drugs.
• After leaving Schering he joined Boehringer Ingelheim to become a Project Manager in Operations.
• He was responsible for the world-wide launches of new products, such as Metalyse and Spiriva. Thereafter he was heading a group called “Launch and Special Supplies”.
• In this function he was responsible for setting up supply chains for Boehringer Ingelheim’s new products. New Supply Chain paradigms and concepts fell also under his responsibility.
• In this context he became the world-wide program leader for BI’s Product Safety & Security project that centers around serialization, track & trace.
• Additionally, Jyrki is leading the global initiative Supply Chain Integrity which takes a broader view on supply chain security, transparency and Risk Management.
KATIE SILK
AstraZeneca
KATIE SILK
AstraZeneca
KATIE SILK, Director Global Security Investigations, AstraZeneca
• Katie joined AstraZeneca as Director of Global Security Investigations in March 2020 – an interesting time to join the company! Her remit is to ensure that illegal trade, including counterfeiting, illegal diversion, and external threats to AZ products and patient safety are investigated globally.
• Katie joined AstraZeneca in the UK as Director of Global Security Investigations in March 2020 – an interesting time to join the company! Her remit is to ensure that illegal trade, including counterfeiting, illegal diversion, and external threats to AZ products and patient safety are investigated globally.
• Katie has 20 years’ of experience in investigations, having worked as an intelligence analyst earlier in her career, before moving to Switzerland and the pharmaceutical industry in 2010. Katie has managed pharma security investigations globally, and also supported Office of Inspector General investigations within a major development aid organisation in Geneva.
ALEXANDRU P
MSD
ALEXANDRU P
MSD
ALEXANDRU POPA, Associate Director, Blockchain for Pharma Supply Chain, MSD
• An engineer at heart, Alex is a T-shaped professional, with deep interdisciplinary knowledge and passion for Digital Transformation in healthcare.
• He enjoyed positions throughout his career in technical operations, solutions delivery, infrastructure architecture, product management, agile transformation, consultancy, innovation, and strategy.
• In his current role, Alex is using both business and technical skills to orchestrate business and technology professionals working diligently to integrate the blockchain with underlying enterprise capabilities, supervise the development of custom-built protocols and applications focused on particular use cases that can relive pain points to challenges in Pharma industry.
FILIPPO D M
GSK Biologicals
FILIPPO D M
GSK Biologicals
FILIPPO DAL MASO, Head of Serialisation & Vaccines Traceability, GSK Biologicals
HEIKO TREFZGER
Roche
HEIKO TREFZGER
Roche
HEIKO TREFZGER, Senior Business Analyst & Product Manager, Roche
Heiko Trefzger, born in 1975, studied business administration with a focus on business informatics. He has almost 25 years of experience in business - IT interfacing functions in chemical and pharmaceutical industries.He is a proven expert in methods and processes in business analysis and solution management. For 20 years he has been working at F. Hofmann-La Roche as a business data processing specialist and business solution manager and has managed numerous strategic and business-critical projects in a global environment.
As a product manager for Data & Insights, artworks and anti-counterfeiting, he has acquired extensive know-how within the supply chain and manufacturing domains. He has received several awards for his activities and projects, including a “CIO Award”, the “Business Process Excellence Award” and, ultimately, for “Distinguished Team Performance” as part of an in-house innovation competition. From 2013 to 2016 he also headed a global Business Solution Manager Forum with over 80 members, successfully introducing standards for methods and processes for business analysis and portfolio management. Heiko Trefzger also lectures at the Cooperative State University in Lörrach.
HUGUES ISEL
Roche
HUGUES ISEL
Roche
HUGUES ISEL, Global Quality Manager - Crisis Management, Roche
My role is Global Quality Manager, dealing on a daily basis with quality and regulatory issues affecting product on the market, but also managing product shortages, and deeply involved as well in fighting against product crime/counterfeits.
DUCCIO L
Menarini
DUCCIO L
Menarini
DUCCIO LOMBARDI, Serialization Normatives Compliance & Anti-Counterfeiting Corporate Quality Unit Head, Menarini
Graduated in Medical and Pharmaceutical Biotechnologies, after the Pharmacology and Innovative Therapies PhD, he focused in the Quality area of the Pharmaceutical Companies field.
Having a broad knowledge of FDA, EMA, MHRA, and other regulations, his first focus was on Data Integrity; later on he decided to step into Serialization and Track and Trace as EU FMD Serialization Quality Unit Responsible in his Company where he mostly focused on Alert Management, competent Authority interface and innovations aimed to enhance Quality within everyday fight against counterfeiting as well as to decrease effort in managing FMD False (positive) Alerts.
He than stepped in the role of Serialization Normatives Compliance and Anti-Counterfeiting Corporate Quality Unit Head focalizing in worldwide Regulative Framework application and Compliance adherence for the Company, as well as having a special focus on innovation and intervention strategies to tackle operative and qualitative issues to worldwide normatives conformity.
CAMILLE DISS
EDGYN
CAMILLE DISS
EDGYN
CAMILLE DISS, CPO, EDGYN
“Camille is Arjo Solutions’ CPO, acting as a solution designer in digital authentication since more than 8 years, she has deployed authentication and traceability project across among others spirits, pharma, cosmetics, precious metal … “
DANIEL L
Zuellig Pharma
DANIEL L
Zuellig Pharma
DANIEL LAVERICK, Chief Digital & Data Officer, Zuellig Pharma
• Daniel Laverick is the Chief Digital & Data Officer at Zuellig Pharma. A strong advocate for the use of technology to drive digital transformation and innovation, Daniel has more than 20 years’ experience working in MNCs across Pharma, Banking, Oil & Gas and Telecoms.
• In his role as Chief Digital & Data Officer for APAC, Daniel is responsible for strategising and leading regional teams across 13 markets to develop new solutions using the latest platforms including the Internet of Things (IoT), Machine Learning, Blockchain and others.
• As an authority on SAP and IT solutions, he previously managed and oversaw the largest SAP migration in Asia to public cloud, along with the development of eZTracker, Asia’s first blockchain-powered end-to-end traceability solution for supply chain connectivity at Zuellig Pharma.
• In addition to overseeing strategy and implementation of the Data & Digital solutions portfolio including Data Analytics, eZRx – a B2B healthcare eCommerce platform, eZHealth – digital health services, and eZTracker, Daniel also actively champions the mission of making healthcare more accessible and believes in empowering the Digital & Data teams to learn more, fail fast, and do good.
RICHARD P M
SIGNAKEY
RICHARD P M
SIGNAKEY
RICHARD P. MCDERMOTT, CEO, SIGNAKEY
• Dr. McDermott was born in England and received his B.Sc. from Salford University and Ph.D. from the University of Leeds
• He emigrated to the U.S. in 1975 to work for a division of WR Grace.
• McDermott acquired that division thru a leveraged buyout in 1981.
• Over the next 35 years, he owned and operated 36 businesses - the largest with annual revenue of $420 million and 1,300 employees.
• Today, with a partner, he owns SignaKey, where he is CEO.
• Signakey lists global clients in Europe, Africa, Asia, and N.A. It is involved diverse track/trace and authentication programs, such as cigarette tax stamps, thoroughbred horseracing, hemp sample tracking, crime-scene evidence traceability, parenteral drugs, automotive racing engines, etc.
SONIA QUEIROS
EMVO
SONIA QUEIROS
EMVO
SONIA QUEIROS, COO, European Medicines Verification Organisation (EMVO)
Education
• Pharmaceutical Sciences Degree from the Faculty of Pharmacy of Oporto University, Oporto, Portugal.
• Master’s in health economics and Policies, School of Economics and Management of Minho University, Braga, Portugal.
• Advanced Studies in Public Policies, School of Sociology and Public Policies of University Institute of Lisbon (ISCTE), Lisbon, Portugal.
Professional Experience
• Chief Operating Officer, European Medicines Verification Organization (EMVO).
• Head of Institutional Affairs (2018-2022), International Affairs (2010-2022), and Head of Brussels office (2016-2020) of the National Association of Pharmacies (ANF) of Portugal.
• Technical Direction of the Domiciliary Distribution of Gasoxmed (Medicinal gas) from January to May 2010.
• Technical Secretary of the Oporto branch of the Portuguese Pharmaceutical Society, from October 2005 to October 2009, Portugal.
• Technical Direction of the wholesale distribution of Ratiopharm (Generics) in Oporto, from March 2003 to December 2005, Portugal.
Other Activities
• President and founding member of the Alumni Association (alumniFFUP) of the Faculty of Pharmacy of Oporto University, since December 2021.
• Member of One FIP Data & Intelligence Commission, 2020-2022.
• Member of the Global Pharmacy Observatory Advisory Committee of FIP (International Federation of Pharmacists), 2017-2020.
• President of the Students Association of the Faculty of Pharmacy of Oporto University (AEFFUP) in 1999/2000, Vice-President in 1998/1999 and member of the board of the Portuguese Pharmacy Students Association (APEF) - Department of Education and Training in 2001/2002.
KASPER ERNEST
Affordable Medicines Europe
KASPER ERNEST
Affordable Medicines Europe
KASPER ERNEST, Secretary General, Affordable Medicines Europe
• Kasper Ernest has worked for the last 11 years in European affairs in Brussels.
• Since 2018, he has been the Secretary-General of Affordable Medicines Europe.
• From 2009-2018 he was with the Confederation of Danish Enterprise, since 2015 serving as Director of the EU & International Department.
• He has also served as the Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance.
• He holds a master’s degree in International Business and Politics from Copenhagen Business School and Singapore Management University.
• He is a guest lecturer at Copenhagen Business School.
PHIL LEWIS
Anti-Counterfeiting Group
PHIL LEWIS
Anti-Counterfeiting Group
PHIL LEWIS, Director General, Anti-Counterfeiting Group (ACG)
• Phil has been engaged in intellectual property enforcement since 2001 when he became the UK government’s Senior Policy Advisor on Intellectual Property Crime and was responsible for developing and leading on the UK’s first National IP Crime Strategy.
• In 2008, Phil joined the European Commission to help develop a Commission strategy against counterfeiting and piracy and was responsible for conceiving and developing the EU Observatory on IP Infringements of IP Rights, which has become the pivotal European network of experts engaged in shaping effective IP enforcement policies and strategies.
• Since retiring from public service, at the end of 2014, Phil worked as Policy and Strategy Adviser to the UK Anti-Counterfeiting Group. He has also been a senior adviser on range of EU IP Enforcement Twinning projects, producing studies and key assessment reports on countries such as Serbia, Ukraine and Macedonia.
• He has been recognized as a major contributor to IP enforcement. In 2014, Phil was awarded the Global Anti-Counterfeiting award for individual achievement and in 2022 he was named the recipient of the IP Champion Award by the Alliance for Intellectual Property.
• In 2018, he became the new Director General of the Anti-Counterfeiting Group.
MIKE ISLES
ASOP EU/EAASM
MIKE ISLES
ASOP EU/EAASM
MIKE ISLES, Executive Director, ASOP EU/EAASM
• Mike is the Executive Director for the Alliance for Safe Online Pharmacy in the EU (www.asop.eu). Its mission is to enable patients to buy their medicines online safely – where it is legal to do so. ASOP EU collaborates strongly with ASOP Global and its members and observers involve many key internet stakeholders. Its aim is to facilitate and campaign for new legislation as well as concrete voluntary actions that will make a real difference and ultimately benefit the health and safety of patients.
• Mike is also Executive Director of the European Alliance for Access to Safe Medicines (www.eaasm.eu), a pan-European non-profit (CIC) patient safety organisation. The EAASM advocates for the development of a robust and harmonisedEU regulatory framework to protect patients and guarantee the safety, quality and efficacy of innovative nanomedicines and nanosimilars. It also campaigns for the safer use of unlicensed/off-label medicines, the adoption of medical, pharmacy and nursing practices that aim to eradicate medication errorsand the exclusion of falsified and substandard medicines from the supply chain.
TONY ORME
Pharma Distr Consult
TONY ORME
Pharma Distr Consult
TONY ORME, Director, Pharma Distribution Consulting
• As a former MHRA Expert GDP Inspector, Tony has over 32 years experience in various areas of the regulation of pharmaceutical distribution. With 22 years within the MHRA GDP Inspectorate team he undertook the most high profile and complex inspections across the UK.
• He was responsible for the UK GDP Inspection strategy and development of the risk based inspection programme. He led on the implementation of the Falsified Medicines Directive Unique Identifier for distributors in the UK and represented MHRA on Board meetings with SecurMed, the NMVO for Northern Ireland.
• He has extensive experience in identifying and tackling the infiltration of falsified and counterfeit medicines into the UK supply chain.
LEYLA HANNBECK
AIMP
Sample Attendees
Event Schedule
Meet and to network with your conference colleagues.
08:30 – Coffee and registration
09:30 – Morning Chair’s opening remarks
GRANT COURTNEY, Founder and CEO, Smarter and Safer Products
MARKET ANALYSIS
09:40 – FDA Office of Criminal Investigations and its International Operations Program and Cyber Crimes Unit
• The US FDA Office of Criminal Investigations (OCI).
• FDA OCI International Operations Program (IOP).
• FDA OCI Cyber Crimes Unit (CcIU).
• Some case samples of non-approved products being imported into the United States.
• Concealment methods of non-approved products being imported into the United States.
LUIS PEREZ, Country Attache for UK, FDA Office of Criminal Investigations
10:20 – Falsified Medicines - Risks and Case Management
HUGUES ISEL, Global Quality Manager - Crisis Management, Roche
11:00 – Morning Coffee & Networking
CHALLENGES & OPPORTUNITIES
11:20 – Keynote Panel Discussion: Efforts to stop counterfeit medicines – How to move forward?
• Counterfeit medicines – Biggest issue for pharma industry, working together to stop counterfeit drugs
• As a company, what should you do to handle the situation better?
• Way into the future? How to prepare for it?
• Lessons to learn from RoW
• Utilize social media to educate the consumer to identify counterfeit drugs
• Impact of technology – making the best out of it
Moderator
GRANT COURTNEY, Founder and CEO, Smarter and Safer Products
Panellists
HEATHER HENSON, Senior Director, Investigations and Intelligence, Genentech (USA)
KATIE SILK, Director Global Security Investigations, AstraZeneca
KASPER ERNEST, Secretary General, Affordable Medicines Europe
MERIEM LOUDIYI, Director of Trademarks and Anti-Falsification Department, Servier
12:20 – Driving Pharma Supply Chain Resilience with Blockchain
• By 2023, over 75% of life science manufacturers are predicted to invest in intelligent supply chain solutions to enable greater resilience.
• Discover how businesses are successfully leveraging serialisation and blockchain to increase supply chain resilience and protect supply chains from counterfeits.
• Explore how technology breaks down data silos, enabling plug-and-play products such as eZTracker, an award-winning blockchain traceability solution that enables secure real-time authentication and data - driven fraud investigation of serialised products for better patient safety.
DANIEL LAVERICK, Chief Digital & Data Officer, Zuellig Pharma
12:40 – Networking luncheon / Exhibition Visit
13:50 – The Art of Anti-Counterfeiting
HEIKO TREFZGER, Senior Business Analyst & Product Manager, Roche
14:30 – Falsified medicines on the Internet – how close are we to achieving real solutions?
• Does the Digital Services Act fulfil its objective and adds to the EU pharmacy Common Logo?
• What is the potential of the US DRUGS Act?
• What measures can the Medicrime Convention implement?
• Could a Google algorithm be used to demote rogue websites to lower search pages?
• How effective can a top level domain name, like DotPharmacy be?
• Is Public awareness still the key to curtailing demand?
MIKE ISLES, Executive Director, ASOP EU / EAASM
15:10 – Afternoon coffee & Networking
FIGHTING FAKES – BRAND PROTECTION
15:30 – The global scope and scale of criminal counterfeiting
• How did this happen?
• The sources
• The impact
• The challenges
• What we need to do
• How ACG is responding
PHIL LEWIS, Director General, Anti-Counterfeiting Group (ACG)
16:10 – European Medicines Verification System: Contributing to a safe medicines supply chain in Europe
• Overview of the European Medicines Verification System (EMVS);
• Achievements accomplished throughout the 4 years of “go-live” in securing supply chain in Europe;
• Impact of Brexit;
• European landscape and current developments of the EMVS.
SONIA QUEIROS, COO, European Medicines Verification Organisation (EMVO)
16:50 – Chairperson’s closing remarks and end of conference
17:00 – 18:00 - Networking Drinks Session
08:30 – Coffee and registration
09:30 – Morning Chair’s opening remarks
GRANT COURTNEY, Founder and CEO, Smarter and Safer Products
09:40 – Homeland security investigation’s global fight against transnational criminal organizations distribution of counterfeit pharmaceuticals
THOMAS WELCH, Deputy Attache, London Office, Department of Homeland Security
ALBERT CABRELLI, Assistant Attache, Homeland Security Investigations (HSI)
10:20 – UK Healthcare Distribution – future challenges and opportunities
• Protecting the legal supply chain against falsified medicines.
• The UK experience with EMVS (the European Medicines Verification System)
• Issues shaping the future of distribution (green and digital transformation, major regulatory changes, shortages, etc..)
TONY ORME, Director, Pharma Distribution Consulting
11:00 – Morning Coffee & Networking
SERIALISATION – TRACK & TRACE
11:20 – Panel Discussion with the experts– Serialisation and track & trace - Improve efficiency and safety in the pharmaceutical supply chain
• Securing your supply chain
• Best practices that organisations should implement for regulatory compliance for serialization
• Marketplace trends and track and trace needs to ensure supply chain visibility
• Technologies that can help you achieve full regulatory compliance
• Gaining value from Serialization: Efficient internal operations
• Practical approach to implementing a serialisation solution – Challenges and Solutions
Moderator
GRANT COURTNEY, Founder and CEO, Smarter and Safer Products
Panellists
JYRKI SYVAERI, Corporate Director Supply Chain Integrity, Boehringer Ingelheim
FILIPPO DAL MASO, Head of Serialisation & Vaccines Traceability, GSK Biologicals
HEIKO TREFZGER, Senior Business Analyst & Product Manager, Roche
DUCCIO LOMBARDI, Serialization Normatives Compliance & Anti-Counterfeiting Corporate Quality Unit Head, Menarini
12:20 – Why the fingerprint technology has taken over physical solutions in brand protection?
• Pharma case study of fingerprint implementation in replacement of security stickers
• Focus on optimization : costs, efficiency, brand protection data
CAMILLE DISS, CPO, EDGYN
12:50 – Networking luncheon / Exhibition Visit
14:00 – Advantages of Digital and Pharma E labelling vs Printing on Paper (Packaging Serialisation)
NEHA MEHTA, Regulatory CMC Facilitator, Novartis
14:30 – How MSD is fighting the fakes with blockchain technology
• Blockchain: What you need to know
• Pharma Industry collaboration efforts - a paradigm shift in the digital age
• Counterfeit: Problem Statement per pharma supply chain ecosystem segments
• How MSD is using blockchain to fight the fakes (case study)
ALEXANDRU POPA, Associate Director, Blockchain for Pharma Supply Chain, MSD
15:10 – Afternoon coffee & Networking
15:30 – SIGNAKEY INSIDE WALL OF GLASS VIAL SATISFIES DSCSA AND FMD SERIALIZATION REQUIREMENTS
• Ten years of development and multiple funded pilots.
• 0.8 x 0.8 mm Signakey nude vial contains GTIN and 20-character serial number.
• Marked and decodes at Pharma line speeds
RICHARD P. MCDERMOTT, CEO, SIGNAKEY
REGULATORY
16:00 – Panel Discussion: Regulatory Perspective – Recent updates and Global developments
• Recent evolving regulatory frameworks towards counterfeit drugs
• Regulatory perspective on counterfeit medicines – what is the global answer to this global plague?
• Most recent track and trace regulations
• Comparing the DSCSA and the EU/FMD
• Regulatory submission pathway in Gulf area – Lessons to be learnt
• Online counterfeits – working together with the regulators to overcome this issue
• Work with regulatory agencies, industry organizations, international agencies
• What governments expect from brand holders and pharmaceutical stakeholders?
Moderator
GRANT COURTNEY, Founder and CEO, Smarter and Safer Products
Panellists
LEYLA HANNBECK, Chief Executive, Association of Independent Multiple Pharmacies
NEHA MEHTA, Regulatory CMC Facilitator, Novartis
16:40 – Chairperson’s closing remarks and end of conference
16:50 – End of 11th Annual Pharma Anti-Counterfeiting & Serialisation 2023
Share
Now
Event Sponsors & Partners
Zuellig Pharma Holdings
• Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible.
• We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.
• The company was started a hundred years ago and has grown to become an over US$15 billion business covering 13 markets with over 13,000 employees.
• Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.
• More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia.
• Since then, our teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
Visit our website: www.zuelligpharma.com
SignaKey LLC
Signakey LLC has been in business since 2010. It is a US-based private company with Headquarters in Clawson, Michigan. In addition to offices on the Eastern and Western sides of the US, there is staff in London, Geneva, Sophia, Pune, and Cape Town.
Signakey is a proprietary 2D symbology not in the public domain. Each Signakey is unambiguously unique, and unlike linear and 2D barcodes, RFID, and magnetic stripes, it cannot be copied or cloned. When linked to the database, a record exists of where it should be until it is retired or decommissioned.
With AES 256-bit encryption for security and 75% error correction, the mark can be decoded when wrapped around 100% of a product circumference.
Signakey can produce 5.19 x 10 ³³ unambiguously unique marks - The European Space Agency estimates 3.5 x 10²² stars in the entire Cosmos.
Printed Signakey labels can be overt, covert, or both. The smallest printed reliably decodable Signakey is 4 x 4 mm @ 1200 dpi. Currently, the smallest reliably decodable Signakey laser marked Signakey is 0.8 x 0.8 mm.
Reading a Signakey is a three-step process. Image capture - Extracting the message from the image - Decrypting the message. The first is local with the camera, then via the Internet to Signakey computers for security.
This methodology is not practical for large-volume printed label applications. Recently, a customer for 2 billion annually revenue stamps (5 million /day) required a DLL (Dynamic Link Library) for encoding/decoding rates of 3,500 per minute.
Visit our website: www.signakey.com
EDGYN
• EDGYN, formerly Arjo Solutions and spin-off of former leading banknotes manufacturer Arjowiggins Security, has been active for more than 20 years in the protection of brands and products, supporting its customers, in the private or governmental sectors, in fighting against illicit trade, securing of their revenues and protecting consumers.
• EDGYN develops and industrializes highly innovative physical or digital authentication solutions and has developed a portfolio of 100+ patents.
• EDGYN is notably a pioneer in digital fingerprint solutions, enabling to authenticate products with a smartphone.
• EDGYN is active in the pharmaceutical, cosmetics, spirits, luxury, agrochemicals and automotive sectors providing security solutions to the leading players in each sector.
• EDGYN is also active in the governmental sector, providing security solutions for tax stamps, ID document or precious metals.
Visit our website: www.edgyn.com
Colorcon
Colorcon is a world leader in developing, supplying, and supporting formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our purpose is to improve health and wellness through convenience, compliance, and safety. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development, and manufacture.
Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance, and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, including 7 film coating plants, 25 technical service laboratories globally and more than 1400 employees exclusively dedicated to its customer base.
Colorcon provides innovative digital on-dose technologies and detection services to verify medications. Colorcon’s on-dose authentication system, SoteriaRx®, provides a level of authenticity, transparency, and brand protection not previously available to the Pharma industry. SoteriaRx delivers a digital security layer to safeguard patients and uphold brand integrity.
Visit our website: www.colorcon.com
Soteria RX
Colorcon is a world leader in developing, supplying, and supporting formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our purpose is to improve health and wellness through convenience, compliance, and safety. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development, and manufacture.
Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance, and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, including 7 film coating plants, 25 technical service laboratories globally and more than 1400 employees exclusively dedicated to its customer base.
Colorcon provides innovative digital on-dose technologies and detection services to verify medications. Colorcon’s on-dose authentication system, SoteriaRx®, provides a level of authenticity, transparency, and brand protection not previously available to the Pharma industry. SoteriaRx delivers a digital security layer to safeguard patients and uphold brand integrity.
Visit our website: www.colorcon.com
Virtue Insight
CONCEPTUALISED BY
Virtue Insight
CONCEPTUALISED BY
Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.
Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.
Testimonials
WCO IPM Manager
Food And Drugs Authority, Ghana Head, Market Surveillance Unit
Element Six Business Development Manager
Bayer Consumer Care AG Head Global Packaging Management
horus security Horus Security Consultancy
Selcia ltd Business Development Director
Novartis International Product Security Analyst
QPQuandary CEO
AstraZeneca Plc Regional Investigations Director EMEA, Global Security
Food And Drugs Authority, Ghana Regulatory Officer ( Safe Disposal of Regulated Products)
SECURIKETT Ulrich & Horn Chief Business Development Officer
Venue Details
Venue:
Pestana Chelsea Bridge Hotel
Address: 354 Queenstown Road ,SW11 8AE
London, UK , SAT-NAV: SW84PP
Phone: +44 20 7062 8000
Get Involved
Speaking Opportunities
Fen Castro
fen@virtueinsight.co.in
+91 44 42108101
Sponsor / Exhibit / Delegate Bookings
Piyush Patel
piyush@virtueinsightevents.com
+44 20 3509 3779
